Shots:
- The NMPA has approved Innovent‘s Tabosun (ipilimumab N01 injection or IBI310) + sintilimab for the neoadj. treatment of stage IIB-III resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer
- Approval was based on the P-III (NeoShot) trial assessing ipilimumab N01 + sintilimab as neoadj. therapy in pts with MSI-H/dMMR colon cancer
- Trial met its 1EP of improved pCR rate & EFS per IDMC, with 41 achieving pCR among the first 50 pts as of Nov 28, 2024; detailed results to be presented & published in the future
Ref: PR Newswire | Image: Innovent | Press Release
Related News: Innovent Biologics Reports the Chinese NMPA Approval of Pecondle (Picankibart) to Treat Plaque Psoriasis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
